vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and SunOpta Inc. (STKL). Click either name above to swap in a different company.
SunOpta Inc. is the larger business by last-quarter revenue ($205.4M vs $183.1M, roughly 1.1× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 0.4%, a 12.9% gap on every dollar of revenue. On growth, SunOpta Inc. posted the faster year-over-year revenue change (16.6% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $12.1M). Over the past eight quarters, SunOpta Inc.'s revenue compounded faster (7.4% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
AMPH vs STKL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $205.4M |
| Net Profit | $24.4M | $816.0K |
| Gross Margin | 46.8% | 12.4% |
| Operating Margin | 19.4% | 3.3% |
| Net Margin | 13.3% | 0.4% |
| Revenue YoY | -1.8% | 16.6% |
| Net Profit YoY | -35.7% | 113.1% |
| EPS (diluted) | $0.51 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $205.4M | ||
| Q2 25 | $174.4M | $191.5M | ||
| Q1 25 | $170.5M | $201.6M | ||
| Q4 24 | $186.5M | $193.9M | ||
| Q3 24 | $191.2M | $175.9M | ||
| Q2 24 | $182.4M | $169.5M | ||
| Q1 24 | $171.8M | $184.4M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $816.0K | ||
| Q2 25 | $31.0M | $4.4M | ||
| Q1 25 | $25.3M | $4.8M | ||
| Q4 24 | $38.0M | $-8.7M | ||
| Q3 24 | $40.4M | $-6.2M | ||
| Q2 24 | $37.9M | $-5.3M | ||
| Q1 24 | $43.2M | $2.9M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | 12.4% | ||
| Q2 25 | 49.6% | 14.8% | ||
| Q1 25 | 50.0% | 15.0% | ||
| Q4 24 | 46.5% | 10.9% | ||
| Q3 24 | 53.3% | 13.0% | ||
| Q2 24 | 52.2% | 12.5% | ||
| Q1 24 | 52.4% | 16.8% |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | 3.3% | ||
| Q2 25 | 24.2% | 5.5% | ||
| Q1 25 | 21.9% | 5.2% | ||
| Q4 24 | 24.2% | 1.4% | ||
| Q3 24 | 29.8% | 0.5% | ||
| Q2 24 | 30.3% | 1.2% | ||
| Q1 24 | 27.9% | 5.5% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 0.4% | ||
| Q2 25 | 17.8% | 2.3% | ||
| Q1 25 | 14.8% | 2.4% | ||
| Q4 24 | 20.4% | -4.5% | ||
| Q3 24 | 21.1% | -3.5% | ||
| Q2 24 | 20.8% | -3.1% | ||
| Q1 24 | 25.1% | 1.6% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $0.01 | ||
| Q2 25 | $0.64 | $0.03 | ||
| Q1 25 | $0.51 | $0.04 | ||
| Q4 24 | $0.74 | $-0.08 | ||
| Q3 24 | $0.78 | $-0.05 | ||
| Q2 24 | $0.73 | $-0.04 | ||
| Q1 24 | $0.81 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $2.2M |
| Total DebtLower is stronger | $608.7M | $250.8M |
| Stockholders' EquityBook value | $788.8M | $162.8M |
| Total Assets | $1.6B | $694.1M |
| Debt / EquityLower = less leverage | 0.77× | 1.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $2.2M | ||
| Q2 25 | $231.8M | $2.2M | ||
| Q1 25 | $236.9M | $2.3M | ||
| Q4 24 | $221.6M | $1.6M | ||
| Q3 24 | $250.5M | $2.9M | ||
| Q2 24 | $217.8M | $3.2M | ||
| Q1 24 | $289.6M | $1.5M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | $250.8M | ||
| Q2 25 | $607.7M | $263.3M | ||
| Q1 25 | $603.9M | $260.6M | ||
| Q4 24 | $601.6M | $265.2M | ||
| Q3 24 | $596.4M | $289.9M | ||
| Q2 24 | $586.9M | $303.1M | ||
| Q1 24 | $594.0M | $258.8M |
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $162.8M | ||
| Q2 25 | $757.5M | $159.8M | ||
| Q1 25 | $751.3M | $154.8M | ||
| Q4 24 | $732.3M | $148.6M | ||
| Q3 24 | $727.7M | $155.0M | ||
| Q2 24 | $713.3M | $158.8M | ||
| Q1 24 | $672.4M | $163.6M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $694.1M | ||
| Q2 25 | $1.6B | $704.9M | ||
| Q1 25 | $1.6B | $690.7M | ||
| Q4 24 | $1.6B | $668.5M | ||
| Q3 24 | $1.5B | $699.3M | ||
| Q2 24 | $1.5B | $704.7M | ||
| Q1 24 | $1.6B | $671.8M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | 1.54× | ||
| Q2 25 | 0.80× | 1.65× | ||
| Q1 25 | 0.80× | 1.68× | ||
| Q4 24 | 0.82× | 1.78× | ||
| Q3 24 | 0.82× | 1.87× | ||
| Q2 24 | 0.82× | 1.91× | ||
| Q1 24 | 0.88× | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $16.3M |
| Free Cash FlowOCF − Capex | $24.6M | $12.1M |
| FCF MarginFCF / Revenue | 13.4% | 5.9% |
| Capex IntensityCapex / Revenue | 4.5% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.35× | 20.03× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $36.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $16.3M | ||
| Q2 25 | $35.6M | $-4.5M | ||
| Q1 25 | $35.1M | $22.3M | ||
| Q4 24 | $29.0M | $33.1M | ||
| Q3 24 | $60.0M | $17.2M | ||
| Q2 24 | $69.1M | $-5.6M | ||
| Q1 24 | $55.3M | $5.3M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $12.1M | ||
| Q2 25 | $25.0M | $-9.2M | ||
| Q1 25 | $24.4M | $9.5M | ||
| Q4 24 | $16.6M | $24.0M | ||
| Q3 24 | $46.2M | $11.7M | ||
| Q2 24 | $63.1M | $-15.3M | ||
| Q1 24 | $46.5M | $-2.3M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | 5.9% | ||
| Q2 25 | 14.3% | -4.8% | ||
| Q1 25 | 14.3% | 4.7% | ||
| Q4 24 | 8.9% | 12.4% | ||
| Q3 24 | 24.1% | 6.6% | ||
| Q2 24 | 34.6% | -9.0% | ||
| Q1 24 | 27.1% | -1.2% |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 2.1% | ||
| Q2 25 | 6.1% | 2.5% | ||
| Q1 25 | 6.3% | 6.3% | ||
| Q4 24 | 6.7% | 4.7% | ||
| Q3 24 | 7.2% | 3.2% | ||
| Q2 24 | 3.3% | 5.7% | ||
| Q1 24 | 5.1% | 4.1% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 20.03× | ||
| Q2 25 | 1.15× | -1.03× | ||
| Q1 25 | 1.39× | 4.63× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
